Data from 7 UK NHS centres 1
This retrospective study investigated the impact of rifaximin-α for secondary prevention of OHE on hospital resource utilisation using real world data from 7 UK centres.
1
Mean number of emergency hospital admissions
Adapted from Orr et al. 2016
- Relative reduction 26.1%, p=0.001
- Absolute reduction 0.5 admissions/person/year
Mean number of emergency hospital admissions decreased from 2.1 admissions/person/year before to 1.6 admissions/person/year during rifaximin-α treatment
1
Data from the IMPRESS study 2,3
A retrospective, observational, multicentre study including 145 patients from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
Hospitalisations per patient
3
All-cause admissions
30-day re-admissions per patient
3
All-cause admissions
In UK clinical practice, treatment with rifaximin-α was associated with significant reductions in hospitalisations per patient at 6 months and 12 months.
2
Safety
- 4% patients (9/145) reported adverse drug reactions (ADRs)
- 4/9 of these patients had C difficile infection and none discontinued treatment
- No serious ADRs were reported
UK/XIF5/0719/0523 DOP: October 2019